Revvity, Inc. announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity’s established Pin-point base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit.
This new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander editing. Additionally, the Pin-point platform’s modular design has shown delivery of ultra-low amounts of deaminase while maintaining clinically-relevant levels of base editing and reducing off-target activity, which leads to enhanced safety. The result is a toolkit for therapeutic applications where control, safety, and reproducibility are paramount.
Profluent’s AI platform designs proteins from the ground up, enabling novel functionality, rapid iteration, and therapeutic precision. When paired with Revvity’s proprietary Pin-point system, scientists gain a fully customizable editing toolkit. This latest collaboration builds on Revvity’s earlier demonstration of the ability to replace Cas9 in the Pin-point system with Profluent’s open-access OpenCRISPRT nuclease, recently published in Nature.
The combination of the Pin-point platform and a carefully curated selection of Profluent’s adenine deaminases are available from Revvity through bundled licensing to significantly expand the number of disease-related mutations that could be addressed using the Pin-point platform and accelerate adoption by therapeutic developers.
Visit Revvity for more information
